MedTrace Logo

Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)

NCT03566693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2021-04-21

No results posted yet for this study

Summary

A study to compare the glycemic and quality of life benefits of diabetes management using Dexcom G6 continuous glucose monitoring (CGM) or self-monitored blood glucose (SMBG) made by study participants and their primary care physicians. Decisions will be based on insights from real-time use and retrospective insights, determined during remote visits.

Participants will have type 2 diabetes and be using basal insulin (with or without oral medications and/or Glucagon-Like-Peptide-1 (GLP-1) analogue) and have an elevated Hemoglobin A1C (HbA1c).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

Dexcom G6 CGM System

continuous glucose monitor

DEVICE

Blood glucose meter

Blue-tooth enabled blood glucose meter

Sponsors & Collaborators

  • Jaeb Center for Health Research

    collaborator OTHER

  • DexCom, Inc.

    lead INDUSTRY

Principal Investigators

  • David Price, MD · DexCom, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2021-01-04
Completion
2021-01-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566693 on ClinicalTrials.gov